Trial on Treatment of Patients With Primary Hyperoxaluria Type I With Pyridoxal-phosphate
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
In this study the investigators will prospectively analyze the reduction of urinary oxalate
excretion under the treatment with PLP in dosages of 5mg/kg/day up to 20 mg/kg/day and serum
level response relationship with PLP as an i.v. solution used orally in 12 patients with
primary hyperoxaluria type I as an inherited autosomal-recessive-disorder leading to
increased endogenous oxalate production, urolithiasis and end stage renal disease.
Phase:
Phase 2
Details
Lead Sponsor:
University of Cologne
Treatments:
Pyridoxal Pyridoxal Phosphate Pyridoxine Vitamin B 6